Acute myeloblastic leukaemia: Graft-versus-host and graft-versus-leukaemia responses to autologous IL-2 activated lymphocytes in rapid and slow disease

Cytokines, Cellular and Molecular Therapy

Volumn 5, Issue 1, 1999, Pages 1-6

  Boughton, B J ^a,b   Simpson, A W ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b Rose Hill Villa   (United Kingdom)

Author keywords

GVHD; GVL; IL 2; Immunotherapy; LAK cells; Leukaemia

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; APHERESIS; ARTICLE; CELL STRAIN K 562; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY TEST; DAUDI CELL; FOLLOW UP; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; HUMAN CELL; IMMUNOTHERAPY; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE; LYMPHOKINE ACTIVATED KILLER CELL; PRIORITY JOURNAL; REMISSION; STATISTICAL ANALYSIS; SURVIVAL RATE;

ADOLESCENT; ADULT; BLOOD CELL COUNT; BONE MARROW; CYTOTOXICITY, IMMUNOLOGIC; GRAFT VS HOST REACTION; GRAFT VS TUMOR EFFECT; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; LEUKEMIA, MYELOCYTIC, ACUTE; MIDDLE AGED; RECOMBINANT PROTEINS; SKIN; TREATMENT OUTCOME;

EID: 0032910736     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Hughes TP, Economou K, Mackinnon S et al, Slow evolution of chronic myeloid leukaemia relapsing after BMT with T-cell depleted donor marrow. Br J Haematol (1989) 73: 462-7.
2. Sullivan KM, Weiden PL, Storb R et al, Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA identical siblings as treatment of acute and chronic leukaemia. Blood (1989) 73: 1720-8.
3. Gottlieb DJ, Brenner MK, Heslop HE et al, A phase I clinical trial of recombinant interleukin-2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease. Br J Cancer (1989) 60: 610-15.
4. Dillman RO, Church C, Oldham RK et al, Inpatient continuous infusion IL2 in 788 patients with cancer. Cancer (1993) 71: 2358-70.
5. Hamon MD, Prentice HG, Gottlieb DJ et al, Immunotherapy with IL2 after ABMT for AML. Bone Marrow Transplant (1993) 11: 399-401.
6. Lim S, Newland AC, Kelly S et al, Continuous IV infusion of high dose recombinant IL2 for acute myeloid leukaemia in a phase II study. Cancer Immunol Immunother (1992) 34: 337-42.
7. Ebert EC, Roberts AI, O'Connell SM et al, Characterisation of an immunosuppressive factor derived from colon cancer cells. J Immunol (1987) 138: 2161-8.
8. Adler A, Chernevik PA, Whiteside TL et al, Interleukin 2 induction of LAK activity in the peripheral blood and bone marrow of acute leukaemia patients. The feasibility of LAK generation in adults with active disease and in remission. Blood (1988) 71: 709-16.
9. Beyunnes MC, Massumoto C, York A et al, Interleukin 2 with or without lymphokine activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute leukaemia. Bone Marrow Transplant (1993) 12: 159-63.
10. O'Brien D, Boughton BJ, High and low affinity IL2 receptors on human leukaemia blast cells. Br J Haematol (1990) 75: 315-16.
11. Rosenberg SA, Aebersold P, Cornetta K et al, Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumour-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med (1990) 323: 570-8.
12. Gaspari AA, Lotze MT, Rosenberg et al, Dermatological changes associated with interleukin-2 administration. J Am Med Assoc (1987) 258: 1624-9.
13. Elliot CJ, Sloane JP, Sanderson KV et al, The histological diagnosis of cutaneous graft versus host disease: relationship of skin changes to marrow purging and other clinical variables. Histopathology (1987) 11: 145-55.
14. Boughton BJ, Simpson AW, Phaure AJ, Beatty C, Graft versus host disease following interleukin 2/lymphokine activated killer cell immunotherapy in a patient with acute myelogenous leukaemia in 2nd complete remission: autologous LAK cells following allogeneic bone marrow transplantation are donor derived. Cancer Immunol Immunother (1995) 41: 68-70.
15. Hayhoe FGH, Whitby L, The management of leukaemia in adults. Br J Haematol (1955) 1: 1-19.
16. Tucker J, Murphy MF, Gregory WM et al, Letter. Br J Haematol (1989) 73: 572-4.
17. Jiang YZ, Kanfer ED, Macdonald JO et al, Letter. Graft versus leukaemia following allogeneic BMT: emergence of cytotoxic T lymphocytes reacting to host leukaemia cells. Bone Marrow Transplant (1991) 8: 253-8.
18. Sykes M, Harty MW, Szot GL, Pearson DA, Short course of high dose -IL2 dissociates GVHD/GVL in mice. Blood (1994) 83: 2560-9.